 |
|
|
| |
Safety, Tolerability, and Pharmacokinetics of BRII-778,
A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects
|
| |
| |
IDWeek 2022 Oct 19-21
David Margolis1, Ji Ma1, Michael Watkins1, Yujin Wang1, Chi-Chi Peng1, Chetana Trivedi1, Xuelian Wei1, Lijie Zhong1, Kamlesh Patel1, Li Yan 1, Zhi Hong1, Jean-Luc Girardet1, Lianhong Xu1
1Brii Biosciences Limited
|
| |
|
|
|
|
|
